Cell therapy trial for active pemphigus vulgaris
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This Phase 1/2 trial tests the safety and dosing of genetically modified immune cells made from your own blood (autologous CAR T or related cells) for active pemphigus vulgaris. It may help control disease that is not adequately managed with standard medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be confirmed to have pemphigus vulgaris (PV), usually by biopsy and positive DSG3 blood testing
- Your pemphigus must be active (not under full control) at the screening visit
- You must have tried at least one standard immunosuppressing medicine and it did not work well enough
- You must be at least 18 years old for the CABA-201 part of the study
- You should not be on high-dose prednisone (above 0.25 mg/kg/day)
- You likely cannot have had certain recent treatments (investigational drugs or anti-CD20/19 medicines like rituximab) unless specific exceptions apply
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
This study compares two treatments for moderate-to-severe pemphigus vulgaris, a rare skin blistering condition. One group gets rituximab plus corticosteroids, the other gets corticosteroids plus azathioprine. It aims to find which combination works better to control the disease with fewer side effects.
This Phase 1 study tests an engineered cell therapy made to help the body in people with MPS I (Hurler-Scheie or Scheie). It is early-stage research, so the main goal is to learn about safety and the best way to treat.
This study tests a new drug called CM313 (an antibody that targets a protein on immune cells) for treating pemphigus, a condition that causes painful blisters on the skin and mouth. The goal is to see if it can reduce blisters and improve quality of life, especially for people who haven't responded well to other treatments.
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
This trial tests an investigational drug called B007 for people with pemphigus, a rare autoimmune disease that causes painful blisters on the skin and inside the mouth. It aims to see if B007 can control the disease and allow patients to reduce other treatments.
Hear when a new Pemphigus Vulgaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.